Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Matrix Metalloproteinase 8: Could it Benefit the CAR-T Cell Therapy of Solid Tumors?- a- Commentary on Therapeutic Potential

Matrix Metalloproteinase 8: Could it Benefit the CAR-T Cell Therapy of Solid Tumors?- a-... Cancer Microenvironment (2018) 11:93–96 https://doi.org/10.1007/s12307-018-0208-2 COMMENTARY Matrix Metalloproteinase 8: Could it Benefit the CAR-T Cell Therapy of Solid Tumors?- a- Commentary on Therapeutic Potential 1,2 1,2 Alireza Mardomi & Saeid Abediankenari Received: 13 February 2018 /Accepted: 19 March 2018 /Published online: 27 March 2018 Springer Science+Business Media B.V., part of Springer Nature 2018 Introduction myeloid lymphoma (AML), Hodgkin lymphoma and mul- tiple myeloma [12–15]. Due to overexpression of CD19 in Since the first experiences with genetically modified T B cell malignancies, this tumor associated antigen has been cells in the 1980s, the concept of adoptive T cell immuno- a target of choice for CAR-T cell therapy of B cell lym- therapy has been evolved extensively [1, 2]. The introduc- phomas. So that, CD19 targeted CAR-T cells have attained tion of chimeric antigen receptor (CAR), an artificially the most successful outcomes with CAR-T cell therapy designed receptor on T cells against desired tumor anti- until now [14, 16]. gens, has propelled the adoptive T cell therapy toward fair Numerous CAR-T cells redirected against a variety of solid outcomes. A CAR is usually consisted up of an extracellu- tumors have been applied in clinical trials. Although these lar single chain fragment http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Microenvironment Springer Journals

Matrix Metalloproteinase 8: Could it Benefit the CAR-T Cell Therapy of Solid Tumors?- a- Commentary on Therapeutic Potential

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/matrix-metalloproteinase-8-could-it-benefit-the-car-t-cell-therapy-of-whxhNlcJio

References (42)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media B.V., part of Springer Nature
Subject
Biomedicine; Cancer Research; Oncology; Immunology; Cell Biology; Biochemistry, general; Biomedicine, general
ISSN
1875-2292
eISSN
1875-2284
DOI
10.1007/s12307-018-0208-2
Publisher site
See Article on Publisher Site

Abstract

Cancer Microenvironment (2018) 11:93–96 https://doi.org/10.1007/s12307-018-0208-2 COMMENTARY Matrix Metalloproteinase 8: Could it Benefit the CAR-T Cell Therapy of Solid Tumors?- a- Commentary on Therapeutic Potential 1,2 1,2 Alireza Mardomi & Saeid Abediankenari Received: 13 February 2018 /Accepted: 19 March 2018 /Published online: 27 March 2018 Springer Science+Business Media B.V., part of Springer Nature 2018 Introduction myeloid lymphoma (AML), Hodgkin lymphoma and mul- tiple myeloma [12–15]. Due to overexpression of CD19 in Since the first experiences with genetically modified T B cell malignancies, this tumor associated antigen has been cells in the 1980s, the concept of adoptive T cell immuno- a target of choice for CAR-T cell therapy of B cell lym- therapy has been evolved extensively [1, 2]. The introduc- phomas. So that, CD19 targeted CAR-T cells have attained tion of chimeric antigen receptor (CAR), an artificially the most successful outcomes with CAR-T cell therapy designed receptor on T cells against desired tumor anti- until now [14, 16]. gens, has propelled the adoptive T cell therapy toward fair Numerous CAR-T cells redirected against a variety of solid outcomes. A CAR is usually consisted up of an extracellu- tumors have been applied in clinical trials. Although these lar single chain fragment

Journal

Cancer Microenvironment – Springer Journals

Published: Mar 27, 2018

There are no references for this article.